Phase 1 Open Label Dose Escalation Study of the Safety and Pharmacokinetics of ME-344 as a Single Agent in Patients With Refractory Solid Tumors

Trial Profile

Phase 1 Open Label Dose Escalation Study of the Safety and Pharmacokinetics of ME-344 as a Single Agent in Patients With Refractory Solid Tumors

Completed
Phase of Trial: Phase I

Latest Information Update: 22 Jun 2015

At a glance

  • Drugs ME 344 (Primary)
  • Indications Carcinoid tumour; Cervical cancer; Leiomyosarcoma; Non-small cell lung cancer; Small cell lung cancer; Solid tumours; Urogenital cancer; Uterine cancer
  • Focus Adverse reactions; First in man; Pharmacokinetics
  • Sponsors MEI Pharma
  • Most Recent Events

    • 04 May 2015 Results published in Cancer, according to a MEI Pharma media release.
    • 04 May 2015 Status changed from active, no longer recruiting to completed, according to a MEI Pharma media release.
    • 21 Apr 2014 Planned End Date changed from 1 Dec 2013 to 1 Dec 2014 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top